SNY Sanofi-Aventis

After-Hours Update: All eyes locked on Sanofi's ($SNY) Q3 print tomorrow morning—the ultimate proxy signal for $NVAX. Algorithmic scanners are tracking their qualitative transcripts for European launch pacing, revenue-recognition windows on today’s $125M cash milestone, and combination pipeline guidance. Smart money ignores retail noise and focuses on pure operating leverage. Cruising this structural turnaround straight up Highway 331. Steady the helm.

$SNY they bought $DVAX which supposedly has the best candidate for a plague vaccine. I’m watching this one, considering the events happening in Russia at the moment. $QQQ $VOO

Pre-Market Update: Sanofi ($SNY) officially smashes Q3 expectations this morning with €14.44B in net sales and an upgraded full-year corporate guidance model. The algorithmic proxy signal is completely green. While the retail boards panic over lagging index noise, institutional fund models are tracking this massive global infrastructure scaling. Sanofi's upgraded commercial footprint directly accelerates the structural monetization and royalty velocity of the Matrix-M adjuvant pipeline. Market makers are shuffling inventory brackets to support the rising technical floor ahead of the Nov 5 print. True enterprise valuation is built on raw partner-led execution data, and the long-term cruise control is set straight up Highway 331. Steady the helm. NVAX SNY

$SNY is sitting on a first and the calendar says 34 days Nov 25 PDUFA, Priority Review, Breakthrough in hand. venglustat for type 3 Gaucher disease LEAP2MONO met both primary endpoints and 3 of 4 key secondaries, the ataxia and cognition score beat enzyme replacement at p equals 0.007 no approved US therapy targets the neurological side of GD3. this one is oral and gets into the brain where enzyme replacement does not reach, trading 41.31 today off a 40.97 close, up about 5.6 percent in 5 sessions after that 39.07 low on Oct 14 imo

$SNY moves on its own more than almost any Nasdaq large cap. 92.7% of its pairs sit in the weak-correlation zone (-0.3 to 0.3). $AAPL: 22.6%. Data as of Jun 20, 2025. Not advice.

$SNY Q3 '26 sales reached €14.4B (+14.3% YoY; +12% underlying), led by Dupixent at €5.7B and 1.5M+ patients. Pharma launches grew 31%, rare diseases 12.6%. Gross margin expanded 2.1pp, operating margin 1.9pp; business EPS +19.6%. FY26 guidance raised to 13–15% sales growth and 15–17% EPS growth. Catalysts in play - Dupixent €25B sales target for 2030 reaffirmed. - Regeneron alliance expands into 4 next-gen immunology assets. - Anti-IL-13 registrational studies targeted late 2027/early 2028. - R&D reset: AI, China partnerships, 12–15 first-in-human studies yearly. - New launches now account for 15% of sales. Risks to watch - 2027 pricing expected slightly negative; Q3 gross-to-net benefit partly one-off. - Cheplapharm/Medley disposals reduce 2027 sales by ~€1.3B. - €500M Regeneron reimbursement headwind in H2 '26. - Amlitelimab and itepekimab stopped; frexalimab Phase III extended. - Dupixent patent expiry post-2030 raises replacement risk. - AMVUTTRA royalties face 2027 uncertainty.

TRADE ALERT: $SNY catalyst runup Entry: $44.00 to $44.50 Stop: $42.15 Targets: $45.30, then $46.11 Score: 74 Nov 25 PDUFA for oral venglustat in type 3 Gaucher, 25 days out. first drug aimed at the brain side of it, where IV enzyme replacement never reached. LEAP2MONO met both primaries and the ataxia and cognition read beat enzyme replacement at p equals 0.007. closed Friday at $44.34, up 2.8% on a Q3 beat, EPS $1.24 vs $0.86 expected, and it is sitting right at the top of its recent range imo. size it like a binary because it is one

25 days out on $SNY imo. Nov 25 PDUFA, oral venglustat in type 3 Gaucher. first drug aimed at the brain side of it, where IV enzyme replacement never reached. LEAP2MONO met both primaries. closed Friday at 44.34, up about 3% on earnings day

Pre-Market Update: Sanofi ($SNY) officially smashes Q3 expectations this morning with €14.44B in net sales and an upgraded full-year corporate guidance model. The algorithmic proxy signal is completely green. While the retail boards panic over lagging index noise, institutional fund models are tracking this massive global infrastructure scaling. Sanofi's upgraded commercial footprint directly accelerates the structural monetization and royalty velocity of the Matrix-M adjuvant pipeline. Market makers are shuffling inventory brackets to support the rising technical floor ahead of the Nov 5 print. True enterprise valuation is built on raw partner-led execution data, and the long-term cruise control is set straight up Highway 331. Steady the helm. NVAX SNY

$SNY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.01 up 17.54% YoY • Reported revenue of $17.25B up 11.64% YoY • Sanofi upgraded FY 2026 guidance: sales are expected to grow by a low-teens percentage at CER, and business EPS at CER is expected to grow by a mid-teens percentage.